Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 8;18(1):320.
doi: 10.1186/s12916-020-01792-7.

LDL-C: lower is better for longer-even at low risk

Peter E Penson  1   2   3 , Matteo Pirro  4 , Maciej Banach  5   6   7
Affiliations

LDL-C: lower is better for longer-even at low risk

Peter E Penson et al. BMC Med. .

Abstract

Background: Low-density lipoprotein cholesterol (LDL-C) causes atherosclerotic disease, as demonstrated in experimental and epidemiological cohorts, randomised controlled trials, and Mendelian randomisation studies.

Main text: There is considerable inconsistency between existing guidelines as to how to effectively manage patients at low overall risk of cardiovascular disease (CVD) who have persistently elevated levels of LDL-C. We propose a step-by-step practical approach for the management of cardiovascular risks in individuals with low (< 1%) 10-year risk of CVD, and elevated (> 140 mg/dL, 3.6 mmol/L) LDL-C. The strategy proposed is based on the level of adherence to lifestyle interventions (LSI), and in case of non-adherence, stepwise practical management, including lipid-lowering therapy, is recommended to achieve a target LDL-C levels (< 115 mg/dL, 3.0 mmol/L).

Conclusions: Further studies are necessary to answer the questions on the long-term efficacy, safety, and cost-effectiveness of the suggested approach. This is critical, considering the ever-increasing numbers of such low-risk patients seen in clinical practice.

Keywords: Cardiovascular disease; Ezetimibe; Low risk; Risk stratification; Statins.

PubMed Disclaimer

Conflict of interest statement

PEP owns four shares in AstraZeneca PLC and has received honoraria and/or travel reimbursement for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Napp, Sanofi; MP has received honoraria and/or travel reimbursement for events sponsored by Amgen, Alfasigma, Mylan, Neopharmed Gentili, Sanofi; MB - speakers bureau: Abbott/Mylan, Akcea, Amgen, Daichii Sankyo, KRKA, MSD, Novartis, Novo-Nordisk, Polpharma, Sanofi, Servier; consultant to Akcea, Amgen, Daichii Sankyo, Esperion, Freia Pharmaceuticals, MSD, Polfarmex, Resverlogix, Sanofi/Regeneron; Grants from Amgen, Mylan, Sanofi, and Valeant.

Figures

Fig. 1
Fig. 1
Proposed approach to the management of cardiovascular risks in individuals with low (< 1%) 10-year risk of cardiovascular disease, but elevated (> 140 mg/dL, 3.6 mmol/L) LDL-C
See this image and copyright information in PMC

References

    1. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472. doi: 10.1093/eurheartj/ehx144. - DOI - PMC - PubMed
    1. Zhang Y, Vittinghoff E, Pletcher MJ, Allen NB, Zeki Al Hazzouri A, Yaffe K, Balte PP, Alonso A, Newman AB, Ives DG, et al. Associations of blood pressure and cholesterol levels during young adulthood with later cardiovascular events. J Am Coll Cardiol. 2019;74(3):330–341. doi: 10.1016/j.jacc.2019.03.529. - DOI - PMC - PubMed
    1. Abdullah SM, Defina LF, Leonard D, Barlow CE, Radford NB, Willis BL, Rohatgi A, McGuire DK, de Lemos JA, Grundy SM, et al. Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease. Circulation. 2018;138(21):2315–2325. doi: 10.1161/CIRCULATIONAHA.118.034273. - DOI - PubMed
    1. Virmani R, Robinowitz M, Geer JC, Breslin PP, Beyer JC, McAllister HA. Coronary artery atherosclerosis revisited in Korean war combat casualties. Arch Pathol Lab Med. 1987;111(10):972–976. - PubMed
    1. McNamara JJ, Molot MA, Stremple JF, Cutting RT. Coronary artery disease in combat casualties in Vietnam. JAMA. 1971;216(7):1185–1187. doi: 10.1001/jama.1971.03180330061012. - DOI - PubMed

Substances